- Home
- IOBT vs INAB Comparison
IOBT vs INAB Comparison
Compare IOBT & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IOBT | INAB |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7M | 14.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IOBT | INAB |
|---|---|---|
| Price | $0.04 | $1.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.25 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 40.5M | 55.9K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.77 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.12 |
| 52 Week High | $2.79 | $4.20 |
Technical Indicators
Market Signals| Indicator | IOBT | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 25.94 | 48.88 |
| Support Level | N/A | $1.35 |
| Resistance Level | $0.22 | $2.11 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 15.92 | 67.86 |
Price Performance
Historical ComparisonAbout IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.